Biotech Company Beam Therapeutics Gains $135 Million in Series B

Beam Therapeutics, a biotechnology company developing precision genetic medicines through base editing, completed a $135 million Series B financing. Participants included new investors Redmile Group, LLC, Cormorant Asset Management, GV, and Altitude Life Science Ventures, along with existing investors F-Prime Capital, ARCH Venture Partners, Eight Roads Ventures, and Omega Funds.

The company plans to use the funds to advance the company’s development of next-generation CRISPR technologies, expand its pipeline of base editing programs, and further extend its scientific and technical leadership.